{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:33:40Z","timestamp":1792510420446,"version":"4.5.0"},"reference-count":300,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Sanofi"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Microbiol Rev"],"published-print":{"date-parts":[[2024,12,10]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n          <jats:p>In the United Kingdom (UK) in 2022\/23, influenza virus infections returned to the levels recorded before the COVID-19 pandemic, exerting a substantial burden on an already stretched National Health Service (NHS) through increased primary and emergency care visits and subsequent hospitalizations. Population groups \u22644 years and \u226565 years of age, and those with underlying health conditions, are at the greatest risk of influenza-related hospitalization. Recent advances in influenza virus vaccine technologies may help to mitigate this burden. This review aims to summarize advances in the influenza virus vaccine landscape by describing the different technologies that are currently in use in the UK and more widely. The review also describes vaccine technologies that are under development, including mRNA, and universal influenza virus vaccines which aim to provide broader or increased protection. This is an exciting and important era for influenza virus vaccinations, and advances are critical to protect against a disease that still exerts a substantial burden across all populations and disproportionately impacts the most vulnerable, despite it being over 80 years since the first influenza virus vaccines were deployed.<\/jats:p>","DOI":"10.1128\/cmr.00025-24","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T13:00:46Z","timestamp":1727960446000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["Recent advances in the influenza virus vaccine landscape: a comprehensive overview of technologies and trials"],"prefix":"10.1128","volume":"37","author":[{"given":"Tristan W.","family":"Clark","sequence":"first","affiliation":[{"name":"School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton","place":["Southampton, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-8741","authenticated-orcid":false,"given":"John S.","family":"Tregoning","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5958-4587","authenticated-orcid":true,"given":"Helen","family":"Lister","sequence":"additional","affiliation":[{"name":"Sanofi","place":["Reading, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Poletti","sequence":"additional","affiliation":[{"name":"Sanofi","place":["Reading, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femy","family":"Amin","sequence":"additional","affiliation":[{"name":"Sanofi","place":["Reading, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Nguyen-Van-Tam","sequence":"additional","affiliation":[{"name":"University of Nottingham School of Medicine","place":["Nottingham, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"World Health Organization. 2023. Influenza (Seasonal) factsheet. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal). Retrieved 8 Aug 2024."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236472"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-016-3128-4"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-09553-0"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02610-1"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30496-X"},{"key":"e_1_3_3_8_2","unstructured":"World Health Organisation and Global Influenza Surveillance & Response System. 2023. Influenza laboratory surveillance information \u2013 virus detections by subtype reported to FluNet. Available from: https:\/\/app.powerbi.com\/view?r=eyJrIjoiZTkyODcyOTEtZjA5YS00ZmI0LWFkZGUtODIxNGI5OTE3YjM0IiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_9_2","unstructured":"European Centre for Disease Prevention and Control. 2023. Seasonal influenza 2022\u22122023 annual epidemiological report for 2023. on ECDC. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/seasonal-influenza-annual-epidemiological-report-2022-2023.pdf. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_10_2","unstructured":"UK Health Security Agency. Surveillance of influenza and other seasonal respiratory viruses in the UK winter 2022 to 2023. Available from: https:\/\/www.gov.uk\/government\/statistics\/annual-flu-reports\/surveillance-of-influenza-and-other-seasonal-respiratory-viruses-in-the-uk-winter-2022-to-2023#surveillance-of-influenza-and-seasonal-respiratory-viruses-in-the-uk. Retrieved 88 AugAugust 2024. Accessed 88 AugAugust 2024"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2013.11.013"},{"key":"e_1_3_3_12_2","unstructured":"GOV.UK. 2022. Influenza: the green book chapter 19. Available from: https:\/\/www.gov.uk\/government\/publications\/influenza-the-green-book-chapter-19. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5061"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2023.5639"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2210825"},{"key":"e_1_3_3_16_2","unstructured":"GOV.UK. 2023. Guidance. National flu immunisation programme 2023 to 2024 letter. Available from: https:\/\/www.gov.uk\/government\/publications\/national-flu-immunisation-programme-plan\/national-flu-immunisation-programme-2023-to-2024-letter. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004462"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.14143"},{"key":"e_1_3_3_19_2","unstructured":"UK Health Security Agency. 2023. Flu vaccination programme 2023 to 2024: information for healthcare practitioners. Available from: https:\/\/www.gov.uk\/government\/publications\/flu-vaccination-programme-information-for-healthcare-practitioners\/flu-vaccination-programme-2023-to-2024-information-for-healthcare-practitioners#contraindications-and-precautions. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005479"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2098630"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.09.048"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.01.004"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-307691"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702090"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1144"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.16950"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30592-2"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47690-9"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.057042"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.8873"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2117967"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.151059"},{"key":"e_1_3_3_34_2","unstructured":"Centers for Disease Control and Prevention (CDC). Types of influenza viruses. Available from: https:\/\/www.cdc.gov\/flu\/about\/viruses\/types.htm. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep45043"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.352"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.07.007"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/v11040346"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.63.3.1239-1246.1989"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1097211"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.66.2.1129-1138.1992"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1980.tb27964.x"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25759"},{"key":"e_1_3_3_44_2","unstructured":"Centers for Disease Control and Prevention (CDC). How flu viruses can change: \u201cDrift\u201d and \u201cShift. Available from: https:\/\/www.cdc.gov\/flu\/about\/viruses\/change.htm. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp038238"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.039"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01719674"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08182"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2023.28.21.2300116"},{"key":"e_1_3_3_50_2","article-title":"Vaccines against influenza: WHO position paper \u2013 May 2022","volume":"97","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. 2022. Vaccines against influenza: WHO position paper \u2013 May 2022. Weekly Epidemiol Record 97","journal-title":"Weekly Epidemiol Record"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2013.10.008"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1874927"},{"key":"e_1_3_3_53_2","first-page":"E115","article-title":"History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines","volume":"57","author":"Barberis I","year":"2016","unstructured":"Barberis I, Myles P, Ault SK, Bragazzi NL, Martini M. 2016. History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines. J Prev Med Hyg 57:E115\u2013E120.","journal-title":"J Prev Med Hyg"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)78541-2"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.92.2392.405"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01013-15"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(78)90068-5"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-89-5-657"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(90)90186-u"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.8.1.17623"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.08.028"},{"key":"e_1_3_3_62_2","unstructured":"US Food and Drug Administration. 2023. Package insert - fluarix quadrivalent. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/fluarix-quadrivalent. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.39.2200753"},{"key":"e_1_3_3_64_2","unstructured":"World Health Organization. 2023. Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season. Available from: https:\/\/www.who.int\/publications\/m\/item\/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-southern-hemisphere-influenza-season. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_65_2","unstructured":"World Health Organization. 2023. Recommended composition of influenza virus vaccines for use in the 2023-2024 northern hemisphere influenza season. Available from: https:\/\/www.who.int\/publications\/m\/item\/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern-hemisphere-influenza-season. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_66_2","unstructured":"MedImmune. Highlights of prescribing information - FluMist Quadrivalent. Available from: https:\/\/www.fda.gov\/media\/160349\/download. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_67_2","unstructured":"The Francis Crick Institute. Worldwide influenza centre lab. Available from: https:\/\/www.crick.ac.uk\/research\/platforms-and-facilities\/worldwide-influenza-centre. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_68_2","unstructured":"World Health Organisation. 2021. Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/341850\/9789240024854-eng.pdf?sequence=1. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01741-X"},{"key":"e_1_3_3_70_2","unstructured":"Public Health England. 2017. Influenza vaccine effectiveness (VE) in adults and children in primary care in the United Kingdom (UK): provisional end-of-season results 2017-18. Available from: https:\/\/assets.publishing.service.gov.uk\/media\/5c6a8d3fed915d4a32cf05e8\/Influenza_vaccine_effectiveness_in_primary_care_2017_2018.pdf. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_71_2","unstructured":"Public Health England. 2016. Influenza vaccine effectiveness (VE) in adults and children in primary care in the United Kingdom (UK): provisional end-of- season results 2016-17. Available from: https:\/\/assets.publishing.service.gov.uk\/media\/5c6a8d46e5274a72bdc02db0\/Influenza_vaccine_effectiveness_in_primary_care_2016_2017.pdf. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_72_2","unstructured":"Public Health England. 2015. Influenza vaccine effectiveness in adults and children in primary care in the UK: provisional end-of-season results 2015-16. Available from: https:\/\/assets.publishing.service.gov.uk\/media\/5c6a8d4ced915d4a30a2e772\/Influenza_vaccine_effectiveness_in_primary_care_2015_2016.pdf. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_73_2","unstructured":"Joint Committee on Vaccination and Immunisation. 2021. Advice on influenza vaccines for 2022\/23. Available from: https:\/\/www.nitag-resource.org\/sites\/default\/files\/2021-10\/JCVI%20Statement%20on%20Influenza%20Vaccines%202022-23.pdf. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7202a1"},{"key":"e_1_3_3_75_2","volume-title":"Seasonal influenza vaccination recommendations and coverage rates in EU\/EEA Member States \u2013 An overview of vaccination recommendations for 2021\u221222 and coverage rates for the 2018\u201319 to 2020\u201321 influenza seasons","author":"European Centre for Disease Prevention and Control","year":"2023","unstructured":"European Centre for Disease Prevention and Control. 2023. Seasonal influenza vaccination recommendations and coverage rates in EU\/EEA Member States \u2013 An overview of vaccination recommendations for 2021\u221222 and coverage rates for the 2018\u201319 to 2020\u201321 influenza seasons. ECDC, Stockholm."},{"key":"e_1_3_3_76_2","unstructured":"Joint Committee on Vaccination and Immunisation. 2018. Advice on influenza vaccines for 2019\/20. Available from: https:\/\/app.box.com\/s\/t5ockz9bb6xw6t2mrrzb144njplimfo0\/file\/334815965677. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_77_2","unstructured":"Joint Committee on Vaccination and Immunisation. 2019. Advice on influenza vaccines for 2020\/21. Available from: https:\/\/app.box.com\/s\/t5ockz9bb6xw6t2mrrzb144njplimfo0\/file\/529004924372. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_78_2","unstructured":"Joint Committee on Vaccination and Immunisation. 2023. Advice on influenza vaccines for 2023\/24. Available from: https:\/\/www.gov.uk\/government\/groups\/joint-committee-on-vaccination-and-immunisation. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1405188"},{"key":"e_1_3_3_80_2","unstructured":"World Health Organization. 2022. Guidance on an adapted evidence to recommendation process for national immunization technical advisory groups. World Health Organization. Available from: https:\/\/iris.who.int\/handle\/10665\/356896. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2012.03.013"},{"key":"e_1_3_3_82_2","unstructured":"Joint Committee on Vaccination and Immunisation. 2013. The flu immunisation programme 2013\/14 \u2013 extension to children. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/225360\/Children_s_flu_letter_2013.pdf. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_83_2","unstructured":"Joint Committee on Vaccination and Immunisation. 2014. Childhood flu immunisation programme: update and provisional roll-out schedule. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/448915\/2014-15_update_and_roll-out_schedule_letter.pdf. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_84_2","unstructured":"Public Health England. 2016. Extension of the Influenza immunisation programme to children in England. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/768945\/Extension_of_the_Influenza_immunisation_programme_to_children_in_England.pdf. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1177\/2054270415577762"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.06.065"},{"key":"e_1_3_3_87_2","unstructured":"World Health Organization. 2023. Pandemic influenza preparedness framework: partnership contribution high-level implementation plan III 2024-2030. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/366981\/9789240070141-eng.pdf?sequence=1. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_88_2","unstructured":"GOV.UK. 2020. UK pandemic preparedness. Available from: https:\/\/www.gov.uk\/government\/publications\/uk-pandemic-preparedness\/uk-pandemic-preparedness. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_89_2","unstructured":"HHS.gov. Objective 1: strategic implementation and deployment of the U.S. national pre-pandemic influenza vaccine stockpile (NPIVS). Available from: https:\/\/aspr.hhs.gov\/legal\/Pandemic-Influenza-Strategy\/Pages\/Objective-1.aspx. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_90_2","unstructured":"Australian Government Department of Health. 2019. Australian health management plan for pandemic influenza. Available from: https:\/\/www.health.gov.au\/sites\/default\/files\/documents\/2022\/05\/australian-health-management-plan-for-pandemic-influenza-ahmppi.pdf. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00592-1"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2005630"},{"key":"e_1_3_3_93_2","unstructured":"GOV.UK. 2023. National risk register 2023 edition. Available from: https:\/\/assets.publishing.service.gov.uk\/media\/64ca1dfe19f5622669f3c1b1\/2023_NATIONAL_RISK_REGISTER_NRR.pdf. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07849-4"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2405371"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-024-01087-1"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","unstructured":"Eisfeld AJ Biswas A Guan L Gu C Maemura T Trifkovic S Wang T Babujee L Dahn R Halfmann PJ Barnhardt T Neumann G Suzuki Y Thompson A Swinford AK Dimitrov KM Poulsen K Kawaoka Y. 2024. Pathogenicity and transmissibility of bovine H5N1 influenza virus. Nature. doi:10.1038\/s41586-024-07766-6","DOI":"10.1038\/s41586-024-07766-6"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q1281"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q1203"},{"key":"e_1_3_3_100_2","unstructured":"Centers for Disease Control and Prevention (CDC). 2024. U.S. case of human avian influenza A(H5) virus reported. Available from: https:\/\/www.cdc.gov\/media\/releases\/2022\/s0428-avian-flu.html. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_101_2","unstructured":"Centers for Disease Control and Prevention. 2024. H5N1 Bird Flu: current situation. Available from: https:\/\/www.cdc.gov\/bird-flu\/situation-summary\/index.html. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_102_2","unstructured":"Centers for Disease Control and Prevention (CDC). 2024. CDC A(H5N1) bird flu response update July 12 2024. Available from: https:\/\/www.cdc.gov\/bird-flu\/spotlights\/h5n1-response-07122024.html. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_103_2","unstructured":"European Centre for Disease Prevention and Control. 2024. Avian flu: increased vigilance recommended. Available from: https:\/\/www.ecdc.europa.eu\/en\/news-events\/avian-flu-increased-vigilance-recommended. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_104_2","unstructured":"UK Health Security Agency. 2023. Investigation into the risk to human health of avian influenza (influenza A H5N1) in England: technical briefing 5. Available from: https:\/\/www.gov.uk\/government\/publications\/avian-influenza-influenza-a-h5n1-technical-briefings\/investigation-into-the-risk-to-human-health-of-avian-influenza-influenza-a-h5n1-in-england-technical-briefing-5. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2347019"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-020-0626-6"},{"key":"e_1_3_3_107_2","unstructured":"AstraZeneca UK Limited. Influenza vaccine (live attenuated nasal). Summary of product characteristics. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/3296\/smpc\/print. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_108_2","unstructured":"Mylan. Influenza virus (surface antigen inactivated). Summary of product characteristics. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/9381\/smpc\/print. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_109_2","unstructured":"Sanofi. Quadrivalent influenza vaccine (split virion inactivated). Summary of product characteristics. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/666\/smpc\/print. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_110_2","unstructured":"Sanofi. Quadrivalent influenza vaccine (recombinant prepared in cell culture). Summary of product characteristics. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/12761\/smpc\/print. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_111_2","unstructured":"Seqirus UK Limited. Adjuvanted quadrivalent influenza vaccine (surface antigen inactivated). Summary of product characteristics. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/12881\/smpc\/print. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_112_2","unstructured":"Seqirus UK Limited. Cell-based quadrivalent Influenza vaccine (surface antigen inactivated). Summary of product characteristics. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/12882\/smpc\/print. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_113_2","unstructured":"UK Health Security Agency. 2023. All influenza vaccines marketed in the UK for the 2023 to 2024 season (text version). Available from: https:\/\/www.gov.uk\/government\/publications\/influenza-vaccines-marketed-in-the-uk\/all-influenza-vaccines-marketed-in-the-uk-for-the-2022-to-2023-season. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12257-022-0115-8"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9090979"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0243-3"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9091032"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1491"},{"key":"e_1_3_3_119_2","unstructured":"World Health Organisation (WHO). Global influenza programme: surveillance & monitoring. Available from: https:\/\/www.who.int\/teams\/global-influenza-programme\/surveillance-and-monitoring\/influenza#:~:text=ILI%20case%20definition within%20the%20last%2010%20days. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_120_2","unstructured":"Centers for Disease Control and Prevention (CDC). Glossary of influenza (Flu) terms. Available from: https:\/\/www.cdc.gov\/flu\/about\/glossary.htm. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.11.019"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12706"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00131-10"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00432-6"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac472"},{"key":"e_1_3_3_126_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.23649"},{"key":"e_1_3_3_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2022.10.005"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216983"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008983.pub3"},{"key":"e_1_3_3_130_2","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13270"},{"key":"e_1_3_3_131_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.0468"},{"key":"e_1_3_3_132_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101331"},{"key":"e_1_3_3_133_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.09.004"},{"key":"e_1_3_3_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.12.056"},{"key":"e_1_3_3_135_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-019901"},{"key":"e_1_3_3_136_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002504"},{"key":"e_1_3_3_137_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.02.088"},{"key":"e_1_3_3_138_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002387"},{"key":"e_1_3_3_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.11.074"},{"key":"e_1_3_3_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(18)30062-2"},{"key":"e_1_3_3_141_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab270"},{"key":"e_1_3_3_142_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.12.015"},{"key":"e_1_3_3_143_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30479-5"},{"key":"e_1_3_3_144_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1689"},{"key":"e_1_3_3_145_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz066"},{"key":"e_1_3_3_146_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(19)30079-8"},{"key":"e_1_3_3_147_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003609"},{"key":"e_1_3_3_148_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.07.019"},{"key":"e_1_3_3_149_2","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12555"},{"key":"e_1_3_3_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.01.023"},{"key":"e_1_3_3_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2023.100327"},{"key":"e_1_3_3_152_2","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1471989"},{"key":"e_1_3_3_153_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.08.028"},{"key":"e_1_3_3_154_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30108-5"},{"key":"e_1_3_3_155_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.10.035"},{"key":"e_1_3_3_156_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.07.048"},{"key":"e_1_3_3_157_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.04.019"},{"key":"e_1_3_3_158_2","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12871"},{"key":"e_1_3_3_159_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2331"},{"key":"e_1_3_3_160_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00702-7"},{"key":"e_1_3_3_161_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024848"},{"key":"e_1_3_3_162_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2332"},{"key":"e_1_3_3_163_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101607"},{"key":"e_1_3_3_164_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19020818"},{"key":"e_1_3_3_165_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001269.pub6"},{"key":"e_1_3_3_166_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004879.pub5"},{"key":"e_1_3_3_167_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004876.pub4"},{"key":"e_1_3_3_168_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2329"},{"key":"e_1_3_3_169_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2330"},{"key":"e_1_3_3_170_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2023-112767"},{"key":"e_1_3_3_171_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106187"},{"key":"e_1_3_3_172_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302099"},{"key":"e_1_3_3_173_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2006.01707.x"},{"key":"e_1_3_3_174_2","doi-asserted-by":"publisher","DOI":"10.1086\/652404"},{"key":"e_1_3_3_175_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18010020"},{"key":"e_1_3_3_177_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1701912"},{"key":"e_1_3_3_178_2","doi-asserted-by":"publisher","DOI":"10.1637\/8343-050208-Reg.1"},{"key":"e_1_3_3_179_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines6020019"},{"key":"e_1_3_3_180_2","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2020.9.1.56"},{"key":"e_1_3_3_181_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(87)90040-7"},{"key":"e_1_3_3_182_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092153"},{"key":"e_1_3_3_183_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1712377114"},{"key":"e_1_3_3_184_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2284386"},{"key":"e_1_3_3_185_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010875"},{"key":"e_1_3_3_186_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9111255"},{"key":"e_1_3_3_187_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.046"},{"key":"e_1_3_3_188_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h6291"},{"key":"e_1_3_3_189_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2074"},{"key":"e_1_3_3_190_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4557-0090-5.00019-7"},{"key":"e_1_3_3_191_2","unstructured":"Australian Government Department of Health. 2023. Statement on the administration of seasonal influenza vaccines in 2023. Available from: https:\/\/www.health.gov.au\/sites\/default\/files\/2023-06\/atagi-advice-on-seasonal-influenza-vaccines-in-2023_0.pdf. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_192_2","unstructured":"Manat\u016b Hauora Ministry of Health. 2020. Immunisation handbook 2020. 11. Influenza. Available from: https:\/\/www.health.govt.nz\/our-work\/immunisation-handbook-2020\/11-influenza#10-4. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_193_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2019.103998"},{"key":"e_1_3_3_194_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-017-0006-x"},{"key":"e_1_3_3_195_2","doi-asserted-by":"publisher","DOI":"10.1086\/599790"},{"key":"e_1_3_3_196_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.003"},{"key":"e_1_3_3_197_2","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1575734"},{"key":"e_1_3_3_198_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00163-y"},{"key":"e_1_3_3_199_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1415684"},{"key":"e_1_3_3_200_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.09.061"},{"key":"e_1_3_3_201_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209604"},{"key":"e_1_3_3_202_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102140"},{"key":"e_1_3_3_203_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.06.026"},{"key":"e_1_3_3_204_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2008.07.027"},{"key":"e_1_3_3_205_2","doi-asserted-by":"publisher","DOI":"10.1038\/213612a0"},{"key":"e_1_3_3_206_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30086-4"},{"key":"e_1_3_3_207_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43842-7"},{"key":"e_1_3_3_208_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir436"},{"key":"e_1_3_3_209_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu654"},{"key":"e_1_3_3_210_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01460-06"},{"key":"e_1_3_3_211_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.10.077"},{"key":"e_1_3_3_212_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines3020373"},{"key":"e_1_3_3_213_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu458"},{"key":"e_1_3_3_214_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw230"},{"key":"e_1_3_3_215_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.25.1700496"},{"key":"e_1_3_3_216_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.08.044"},{"key":"e_1_3_3_217_2","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12801"},{"key":"e_1_3_3_218_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868110-00002"},{"key":"e_1_3_3_219_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jip.2011.05.003"},{"key":"e_1_3_3_220_2","unstructured":"Seqirus UK Limited. Cell-based quadrivalent influenza vaccine (Surface Antigen Inactivated) seqirus suspension for injection in pre-filled syringe. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/12882\/smpc. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_221_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0079-z"},{"key":"e_1_3_3_222_2","unstructured":"Centers for Disease Control and Prevention (CDC). How influenza (flu) vaccines are made. Available from: https:\/\/www.cdc.gov\/flu\/prevent\/how-fluvaccine-made.htm#recombinant. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_223_2","unstructured":"Centers for Disease Control and Prevention. Cell-based flu vaccines. Available from: https:\/\/www.cdc.gov\/flu\/prevent\/cell-based.htm. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_224_2","doi-asserted-by":"publisher","DOI":"10.1177\/2515135520908121"},{"key":"e_1_3_3_225_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2019.05.012"},{"key":"e_1_3_3_226_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00415-3"},{"key":"e_1_3_3_227_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2018.08.012"},{"key":"e_1_3_3_228_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608862"},{"key":"e_1_3_3_229_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00403-7"},{"key":"e_1_3_3_230_2","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201400438"},{"key":"e_1_3_3_231_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.07.128"},{"key":"e_1_3_3_232_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.08.018"},{"key":"e_1_3_3_233_2","doi-asserted-by":"publisher","DOI":"10.26633\/RPSP.2017.158"},{"key":"e_1_3_3_234_2","unstructured":"UK Health Security Agency. 2024. Surveillance of influenza and other seasonal respiratory viruses in the UK winter 2023 to 2024. Available from: https:\/\/www.gov.uk\/government\/statistics\/surveillance-of-influenza-and-other-seasonal-respiratory-viruses-in-the-uk-winter-2023-to-2024\/surveillance-of-influenza-and-other-seasonal-respiratory-viruses-in-the-uk-winter-2023-to-2024#vaccination. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_235_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7308a3"},{"key":"e_1_3_3_236_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.030"},{"key":"e_1_3_3_237_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.01.006"},{"key":"e_1_3_3_238_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01140.x"},{"key":"e_1_3_3_239_2","unstructured":"Central Drugs Standard Control Organization. Corona virus 2019-nCoV vaccine (Recombinant) summary of product characteristics. Available from: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadSmPC\/6.%20ZyCoVD%203mg_Cadila_SmPC %20Factsheet %20PI.pdf. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_240_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-02385-x"},{"key":"e_1_3_3_241_2","doi-asserted-by":"publisher","DOI":"10.2217\/fvl-2021-0170"},{"key":"e_1_3_3_242_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243"},{"key":"e_1_3_3_243_2","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2202278"},{"key":"e_1_3_3_244_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41354-y"},{"key":"e_1_3_3_245_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032700"},{"key":"e_1_3_3_246_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32149-8"},{"key":"e_1_3_3_247_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.06.008"},{"key":"e_1_3_3_248_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.102045"},{"key":"e_1_3_3_249_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000948"},{"key":"e_1_3_3_250_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28572"},{"key":"e_1_3_3_251_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.710647"},{"key":"e_1_3_3_252_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02432-1"},{"key":"e_1_3_3_253_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222178"},{"key":"e_1_3_3_254_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123969"},{"key":"e_1_3_3_255_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0016-6"},{"key":"e_1_3_3_256_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206837"},{"key":"e_1_3_3_257_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2015.08.006"},{"key":"e_1_3_3_258_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit180"},{"key":"e_1_3_3_259_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70240-7"},{"key":"e_1_3_3_260_2","unstructured":"ModernaTX Inc. A study of mRNA-1010 seasonal influenza vaccine in adults (NCT05415462). Accessed August 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT05415462?term=NCT05415462&rank=1."},{"key":"e_1_3_3_261_2","unstructured":"ModernaTX Inc. A study of mRNA-1010 seasonal influenza vaccine in adults 50 years old and older (NCT05566639). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05566639?term=mRNA-1010&aggFilters=phase:3&rank=3. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_262_2","unstructured":"Sanofi Pasteur. Study to assess the safety and immunogenicity of monovalent mRNA NA vaccine in adult participants 18 years of age and older (NCT05426174). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05426174?cond=influenza&intr=%20mRNA%20QIV&rank=4. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_263_2","unstructured":"Sanofi Pasteur. Safety and immunogenicity of quadrivalent influenza mRNA vaccine MRT5410 in adult participants 18 years of age and older (NCT05624606). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05624606?cond=influenza&intr=%20mRNA%20QIV&rank=1. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_264_2","unstructured":"Sanofi Pasteur. Safety and immunogenicity of quadrivalent influenza mRNA vaccine MRT5413 in adult participants 18 years of age and older (NCT05650554). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05650554?cond=influenza&intr=%20mRNA%20QIV&rank=2. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_265_2","unstructured":"Sanofi Pasteur. Safety and immunogenicity of quadrivalent influenza mRNA vaccine MRT5407 in adult participants18 years of age and older (NCT05553301). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05553301?cond=influenza&intr=%20mRNA%20QIV&rank=3. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_266_2","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). A study to evaluate the safety and immunogenicity of two doses of DCVC H1 HA mRNA-LNP in healthy adults (NCT05945485). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05945485?cond=influenza&intr=%20mRNA%20QIV&rank=8. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_267_2","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). A study to evaluate the safety and immunogenicity of a single dose of H1ssF-3928 mRNA-LNP in healthy adults (NCT05755620). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05755620?cond=influenza&intr=%20mRNA%20QIV&rank=9. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_268_2","unstructured":"Seqirus. Safety reactogenicity and immunogenicity study of a self-amplifying mRNA influenza vaccine in healthy adults (NCT06028347). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06028347?cond=influenza&intr=%20mRNA&rank=1. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_269_2","unstructured":"GlaxoSmithKline. A study to assess the safety and immune response of a vaccine against influenza in healthy younger and older adults (NCT05823974). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05823974?cond=influenza&intr=%20mRNA&rank=7. Retrieved 8 Aug 2024. 8 Aug 2024"},{"key":"e_1_3_3_270_2","unstructured":"GlaxoSmithKline. A study on the safety reactogenicity and immune response of a vaccine against influenza in healthy younger and older adults (NCT05446740). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05446740?cond=influenza&intr=%20mRNA&page=2&rank=16. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_271_2","unstructured":"CureVac. A study to evaluate the safety reactogenicity and immunogenicity of vaccine CVSQIV in healthy adults (NCT05252338). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05252338?cond=influenza&intr=%20mRNA&page=3&rank=27. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_272_2","unstructured":"Arcturus Therapeutics Inc. Safety and immunogenicity first-in-human dose-ranging study of self-amplifying RNA seasonal influenza vaccine in adults (NCT06125691). Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06125691?cond=influenza&intr=%20mRNA&page=3&rank=28. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_273_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae329"},{"key":"e_1_3_3_274_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.074"},{"key":"e_1_3_3_275_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01408-5"},{"key":"e_1_3_3_276_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00503-y"},{"key":"e_1_3_3_277_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00369-6"},{"key":"e_1_3_3_278_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.07.043"},{"key":"e_1_3_3_279_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.673699"},{"key":"e_1_3_3_280_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"e_1_3_3_281_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.09.057"},{"key":"e_1_3_3_282_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bej.2020.107757"},{"key":"e_1_3_3_283_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32014-6"},{"key":"e_1_3_3_284_2","doi-asserted-by":"publisher","DOI":"10.3390\/v12050518"},{"key":"e_1_3_3_285_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-011-9632-5"},{"key":"e_1_3_3_286_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.03.023"},{"key":"e_1_3_3_287_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1362515"},{"key":"e_1_3_3_288_2","unstructured":"ClinicalTrials.gov. A study to evaluate the safety tolerability and immunogenicity of combined modified RNA vaccine candidates against COVID-19 and influenza. ClinicalTrials.gov Identifier: NCT05596734. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05596734. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_289_2","unstructured":"ClinicalTrials.gov. A Study of mRNA-based influenza and SARS-CoV-2 (COVID-19) multi-component vaccines in healthy adults. ClinicalTrials.gov identifier: NCT05827926. Retrieved 8 Aug 2024. https:\/\/clinicaltrials.gov\/study\/NCT05827926."},{"key":"e_1_3_3_290_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-02121-1"},{"key":"e_1_3_3_291_2","unstructured":"ClinicalTrials.gov. A study of mRNA-1083 (SARS-CoV-2 and influenza) vaccine in healthy adult participants \u226550 years of age. Retrieved 12 Aug 2024. https:\/\/clinicaltrials.gov\/study\/NCT06097273."},{"key":"e_1_3_3_292_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02163-13"},{"key":"e_1_3_3_293_2","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-153"},{"key":"e_1_3_3_294_2","unstructured":"World Health Organisation. Global influenza programme. Available from: https:\/\/www.who.int\/teams\/global-influenza-programme\/vaccines. Retrieved 8 Aug 2024."},{"key":"e_1_3_3_295_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep15279"},{"key":"e_1_3_3_296_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9010026"},{"key":"e_1_3_3_297_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105505"},{"key":"e_1_3_3_298_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00024-X"},{"key":"e_1_3_3_299_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1118-7"},{"key":"e_1_3_3_300_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-00990-1"},{"key":"e_1_3_3_301_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(16)30044-5"},{"key":"e_1_3_3_302_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00493-5"}],"container-title":["Clinical Microbiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/cmr.00025-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/cmr.00025-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T14:04:40Z","timestamp":1733839480000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/cmr.00025-24"}},"subtitle":[],"editor":[{"given":"Graeme N.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":300,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12,10]]}},"alternative-id":["10.1128\/cmr.00025-24"],"URL":"https:\/\/doi.org\/10.1128\/cmr.00025-24","relation":{},"ISSN":["0893-8512","1098-6618"],"issn-type":[{"value":"0893-8512","type":"print"},{"value":"1098-6618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"assertion":[{"value":"2024-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00025-24"}}